Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
EP300-interacting inhibitor of differentiation 2B (EID2B)
- Target
- EID2B
- Molecular classification
- Other (transcriptional repressor), protein-protein interaction regulator
01
Overview
EP300-interacting inhibitor of differentiation 2B (EID2B) is a protein encoded by the human EID2B gene. It acts as a nuclear repressor of MYOD-dependent transcription, glucocorticoid receptor-dependent transcription, and muscle differentiation by enabling identical protein binding activity and negatively regulating DNA-templated transcription and myoblast differentiation. EID2B is similar in function and structure to EID2 and can interact with other family members to modulate transcriptional responses, but is not classified as a canonical therapeutic target, such as an enzyme, receptor, transporter, or ion channel. There is currently no evidence of direct disease association, biomarker use, or druggability for EID2B[4][8].
- Other names
- EID2BEID3EID-2BEID-3FLJ38944EID-2-like inhibitor of differentiation 3EP300-interacting inhibitor of differentiation 2BEID-2-like inhibitor of differentiation-3
02
Biological functions
Negative regulation of DNA-templated transcriptionnegative regulation of myoblast differentiationrepression of MYOD-dependent and glucocorticoid receptor-dependent transcription
Beyond the preview
Go deeper on EP300-interacting inhibitor of differentiation 2B (EID2B).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EP300-interacting inhibitor of differentiation 2B (EID2B).